Martine Rothblatt, Chairperson and Chief Executive Officer of United Therapeutics Corp (NASDAQ: UTHR), carried out a matched exercise-and-sale of company stock on March 26, 2026, executing multiple transactions that resulted in approximately $5.09 million in proceeds.
Transaction details
On March 26, 2026, Rothblatt exercised stock options to acquire 9,500 shares of United Therapeutics common stock at an exercise price of $146.03, for a total value of $1,387,285. The same day, she sold 9,500 common shares in several transactions, with sale prices ranging from $530.9494 to $539.98, producing roughly $5.09 million in aggregate proceeds.
Post-transaction holdings
Following the exercise and subsequent disposition, Rothblatt directly holds 40,513 shares of United Therapeutics common stock. Additional indirect holdings reported include 166 shares held by spouse, and trust holdings of 324,518 shares, 258,117 shares, 45,596 shares and 10,962 shares.
Trading plan and timeline
The option exercise and sale of the resulting common shares were conducted under a pre-arranged 10b5-1 trading arrangement that Rothblatt adopted on November 7, 2025. The plan is scheduled to remain in effect until the earlier of two outcomes: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.
Corporate developments
United Therapeutics also released results from its phase 3 TETON-2 clinical study, which assessed nebulized Tyvaso for the treatment of idiopathic pulmonary fibrosis. The company said the study met its primary endpoint, demonstrating a statistically significant improvement in lung function versus placebo over a 52-week period.
Alongside the clinical news, United Therapeutics announced a new $2.0 billion stock repurchase program. The company executed an initial $1.5 billion accelerated share repurchase agreement with Citibank, leaving $500 million available for additional repurchases at the company’s discretion.
Analyst actions
Following these developments, TD Cowen reiterated a Buy rating on United Therapeutics and kept a price target of $575. Cantor Fitzgerald raised its price target to $625, citing expectations tied to the company’s TETON-1 trial.
Context and takeaway
The matched exercise-and-sale was performed pursuant to a pre-set trading plan and occurred on the same day as material corporate updates including positive phase 3 data and a substantial repurchase program. The reported transactions, plan parameters and the company’s recent strategic disclosures are all documented in the filings and announcements accompanying these events.
Key points
- CEO Martine Rothblatt exercised 9,500 options at $146.03 and sold 9,500 shares on March 26, 2026, generating approximately $5.09 million in sale proceeds - impacting shareholders and equity markets in the healthcare and biotech sector.
- The stock transactions were conducted under a 10b5-1 plan adopted November 7, 2025, which remains in force until specified option exercise or the end of 2026 - relevant for corporate governance and insider trading oversight in the public markets.
- United Therapeutics announced positive phase 3 TETON-2 results for nebulized Tyvaso in idiopathic pulmonary fibrosis and launched a $2 billion repurchase program, including a $1.5 billion ASR with Citibank - important for equity valuation and capital allocation in the biotech sector.
Risks and uncertainties
- The 10b5-1 plan remains active only until the earlier of certain option exercises or December 31, 2026, introducing timing uncertainty around any future intended exercises or sales - relevant to investors monitoring insider activity.
- Of the $2.0 billion repurchase authorization, $500 million is discretionary and therefore subject to future company decisions, creating uncertainty about the extent and timing of further buybacks - affecting market supply dynamics for the company’s shares.
- Analyst outlooks reference expectations for the TETON-1 trial, implying that future trial outcomes could influence investor sentiment and valuation, though the article does not provide results for that trial.